Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Live updates as we join the police on a soaking Friday night
08:56pm, Friday, 12'th Jun 2020
Crime reporter Carl Eve is out with Plymouth's neighbourhood teams this evening as they police the city on a soggy Friday night
Drama as man rages at police who tried to save his life
08:55pm, Friday, 12'th Jun 2020
The incident happened in Plymouth city centre tonight
Arvinas Appoints Linda Bain to its Board of Directors
11:00am, Thursday, 11'th Jun 2020
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why
04:00pm, Friday, 05'th Jun 2020
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
11:00am, Friday, 05'th Jun 2020
NEW HAVEN, Conn., June 05, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.
From the coronavirus frontline, doctors recall battling SA's HIV outbreak
10:15am, Saturday, 30'th May 2020
After years spent fighting the spread of HIV in impoverished overcrowded settlements, veteran health workers like Goemaere are offering valuable insight for South Africa's coronavirus response.
P/E Ratio Insights for Arvinas
02:28pm, Friday, 29'th May 2020
Looking into the current session, Arvinas Inc. (NASDAQ: ARVN) is trading at $34.69, after a 22.65% drop. Over the past month, the stock decreased by 32.30%, but over the past year, it actually went up
Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated data from the dose escalation portion of the c
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders
08:30pm, Wednesday, 20'th May 2020
Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be he
Gold climbs on the back of poor US retail figures, fears of more COVID-19 infections - Stockhead
01:02am, Monday, 18'th May 2020
Gold is on a tear with prices testing a one-month high due to disappointing economic data from the US and fears of a second wave of COVID-19 infections, which has dimmed hopes of a swift recovery. Spo
Here's Why Arvinas Shares Are Tumbling 13.7% Today
04:33pm, Thursday, 14'th May 2020
Investors were hoping for better initial data from an early-stage trial of its prostate cancer therapy.
5 ASCO Abstracts Moving Biopharma Stocks
12:00am, Thursday, 14'th May 2020
The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from...
- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of.
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
12:00am, Wednesday, 13'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
